Gatralimab（Cat No.:I042091）is an investigational monoclonal antibody that targets the immune checkpoint protein TIGIT (T-cell immunoreceptor with Ig and ITIM domains), which plays a role in suppressing T-cell activity and immune responses, particularly in the tumor microenvironment. By inhibiting TIGIT, gatralimab aims to enhance T-cell activation and promote stronger anti-tumor immunity. It is being studied in clinical trials for various cancers, including non-small cell lung cancer (NSCLC) and melanoma. Gatralimab’s potential as a monotherapy or in combination with other immunotherapies is being evaluated to improve immune responses and cancer treatment outcomes.
